<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">systhiper-457</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КАРДИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>Диуретики в составе комбинированной антигипертензивной терапии: фокус на прогноз</article-title><trans-title-group xml:lang="en"><trans-title>Diuretics in combination antihypertensive therapy: focus on forecast</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чазова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Chazova</surname><given-names>I. E.</given-names></name></name-alternatives><email xlink:type="simple">chazova@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мартынюк</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Martyniuk</surname><given-names>T. V.</given-names></name></name-alternatives><email xlink:type="simple">trukhiniv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт клинической кардиологии им. А.Л.Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.L.Myasnikov Institute of Clinical Cardiology Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>13</volume><issue>2</issue><fpage>6</fpage><lpage>10</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чазова И.Е., Мартынюк Т.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Чазова И.Е., Мартынюк Т.В.</copyright-holder><copyright-holder xml:lang="en">Chazova I.E., Martyniuk T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/457">https://www.syst-hypertension.ru/jour/article/view/457</self-uri><abstract><p>В современной терапии артериальной гипертонии (АГ) тиазидные диуретики наряду с b-адреноблокаторами, антагонистами кальция, ингибиторами ангиотензинпревращающего фермента и блокаторами рецепторов ангиотензина рассматриваются для начальной и поддерживающей антигипертензивной терапии в виде моно - или комбинированной терапии. Пять указанных классов препаратов обладают сопоставимой антигипертензивной эффективностью и доказанным влиянием на прогноз в соответствии с результатами рандомизированных контролируемых клинических исследований. Наибольшее распространение в широкой клинической практике для лечения больных АГ получили тиазидные (тиазидоподобные) диуретики. Наиболее мощной доказательной базой среди диуретиков в отношении влияния на прогноз имеет хлорталидон (ХТД). В статье представлены данные рандомизированных плацебо-контролируемых и сравнительных исследований ХТД и гидрохлоротиазида при АГ. Показано, что диуретики являются наиболее оправданным компонентом комбинированной терапии. Применение новой фиксированной комбинации ХТД в сочетании с азилсартана медоксомилом в нашей стране позволит улучшить возможности эффективного лечения этой категории больных.</p></abstract><trans-abstract xml:lang="en"><p>In the modern therapy of arterial hypertension (AH) along with thiazide diuretics b-blockers, calcium antagonists, angiotensin converting enzyme inhibitors and angiotensin receptor blockers are considered for initial and maintenance of antihypertensive therapy in the form of mono - or combination therapy. Five of these classes of drugs have comparable antihypertensive effectiveness and proven impact on prognosis in accordance with the results of randomized controlled clinical trials. The most widely used in clinical practice for the treatment of patients with AH received thiazide diuretics. The most powerful evidence base among the diuretics in regards to the effect on prognosis is chlortalidone. The article presents data from a randomized, placebo-controlled and comparative studies сhlortalidone and hydrochlorothiazide in AH. It is shown that diuretics are the most effective component of combination therapy. The application of a new fixed combination сhlortalidone in combination with azilsartan medoxomil in our country will improve opportunities for effective treatment of this category of patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>диуретики</kwd><kwd>хлорталидон</kwd><kwd>гидрохлоротиазид</kwd><kwd>азилсартан</kwd><kwd>монотерапия</kwd><kwd>комбинированная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>diuretics</kwd><kwd>chlortalidone</kwd><kwd>hydrochlorothiazide</kwd><kwd>azilsartan</kwd><kwd>monotherapy</kwd><kwd>combination therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертониии Всероссийского научного общества кардиологов)//Системные гипертензии. 2010; 7 (3): 5-26.</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертониии Всероссийского научного общества кардиологов)//Системные гипертензии. 2010; 7 (3): 5-26.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Леонова М.В., Штейнберг Л.Л., Белоусов Д.Ю. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV: приверженность врачей. РМЖ. 2015; 1 (117): 59-66.</mixed-citation><mixed-citation xml:lang="en">Леонова М.В., Штейнберг Л.Л., Белоусов Д.Ю. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV: приверженность врачей. РМЖ. 2015; 1 (117): 59-66.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и др. Анализ врачебной практики проведения антигипертензивной терапии в России (по данным исследования ПИФАГОР III). Фарматека. 2009; 2: 98-103.</mixed-citation><mixed-citation xml:lang="en">Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и др. Анализ врачебной практики проведения антигипертензивной терапии в России (по данным исследования ПИФАГОР III). Фарматека. 2009; 2: 98-103.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12.</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Veterans Administration Cooperative Study on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. JAMA 1967; 202: 116-22.</mixed-citation><mixed-citation xml:lang="en">Veterans Administration Cooperative Study on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. JAMA 1967; 202: 116-22.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">SHEP Cooperative Research Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255-64.</mixed-citation><mixed-citation xml:lang="en">SHEP Cooperative Research Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255-64.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium - channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.</mixed-citation><mixed-citation xml:lang="en">The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium - channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Peterzan M.A, Hardy R, Chaturvedi N, Hughes A.D. Meta - analysis of dose - response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104-9.</mixed-citation><mixed-citation xml:lang="en">Peterzan M.A, Hardy R, Chaturvedi N, Hughes A.D. Meta - analysis of dose - response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Psaty B.M, Lumley T, Furberg C.D et al. Health outcomes associated with various antihypertensive therapies used as first - line agents: a network meta - analysis. JAMA 2003; 289: 2534-44.</mixed-citation><mixed-citation xml:lang="en">Psaty B.M, Lumley T, Furberg C.D et al. Health outcomes associated with various antihypertensive therapies used as first - line agents: a network meta - analysis. JAMA 2003; 289: 2534-44.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: Effects of various classes of antihypertensive drugsoverview and meta - analyses. J Hypertens 2015; 33 (2): 195-211.</mixed-citation><mixed-citation xml:lang="en">Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: Effects of various classes of antihypertensive drugsoverview and meta - analyses. J Hypertens 2015; 33 (2): 195-211.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA 1982; 248: 1465-77.</mixed-citation><mixed-citation xml:lang="en">Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA 1982; 248: 1465-77.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Carter B.L, Ernst M.E, Cohen J.D. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9.</mixed-citation><mixed-citation xml:lang="en">Carter B.L, Ernst M.E, Cohen J.D. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Кurtz T.W. Chlorthalidone: don’t call it “thiazide - like” anymore. Hypertension 2010; 56: 335-7.</mixed-citation><mixed-citation xml:lang="en">Кurtz T.W. Chlorthalidone: don’t call it “thiazide - like” anymore. Hypertension 2010; 56: 335-7.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Liebson P.R, Grandits G.A, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional - hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91 (3): 698-706.</mixed-citation><mixed-citation xml:lang="en">Liebson P.R, Grandits G.A, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional - hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91 (3): 698-706.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Materson B.J, Oster J.R, Michael U.F et al. Dose response to chlorthalidone in patients with mild hypertension, efficacy of a lower dose. Clin Pharmacol Ther 1978; 24: 192-8.</mixed-citation><mixed-citation xml:lang="en">Materson B.J, Oster J.R, Michael U.F et al. Dose response to chlorthalidone in patients with mild hypertension, efficacy of a lower dose. Clin Pharmacol Ther 1978; 24: 192-8.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Khosla N, Chua D.Y, Elliott W.J, Bakris G.L. Are chlorthalidone and hydrochlorothiazide equivalent blood - pressure - lowering medications? J Clin Hypertens (Greenwich) 2005; 7 (6): 354-6.</mixed-citation><mixed-citation xml:lang="en">Khosla N, Chua D.Y, Elliott W.J, Bakris G.L. Are chlorthalidone and hydrochlorothiazide equivalent blood - pressure - lowering medications? J Clin Hypertens (Greenwich) 2005; 7 (6): 354-6.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Musini V, Nazer M, Bassett K et al. Blood pressure - lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; 5: CD003824; doi: 10.1002/14651858.CD003824.pub2.</mixed-citation><mixed-citation xml:lang="en">Musini V, Nazer M, Bassett K et al. Blood pressure - lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; 5: CD003824; doi: 10.1002/14651858.CD003824.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода С.В. Азилсартан: расширит ли он возможности лечения артериальной гипертензии? Кардиология. 2015: 4: 97-100.</mixed-citation><mixed-citation xml:lang="en">Недогода С.В. Азилсартан: расширит ли он возможности лечения артериальной гипертензии? Кардиология. 2015: 4: 97-100.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bakris G, Sica D, White W.B et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1229. e1-1229.e10.</mixed-citation><mixed-citation xml:lang="en">Bakris G, Sica D, White W.B et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1229. e1-1229.e10.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Calhoun D.A, Jones D, Textor S et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526.</mixed-citation><mixed-citation xml:lang="en">Calhoun D.A, Jones D, Textor S et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
